Norleual 

Norleual, an angiotensin (Ang) IV analog, is a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC₅₀ of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities^[1].

Norleual at 20 and 50 pM significantly reduces HGF-dependent c-Met and Gab1 phosphorylation. 20 pM Norleual dramatically reduces HGF-initiated association between Gab1 and c-Met in HEK293 cells. Norleual markedly attenuates HGF-dependent c-Met activation and downstream signaling^[1]. Norleual (1 pM-1 μM; 4 days) is able to inhibit HGF-dependent signaling, proliferation, migration, and invasion in multiple cell types at concentrations in the picomolar range in MDCK cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Norleual (50 μg/kg; intraperitoneal injection; daily; for 2 weeks; C57BL/6 mice) suppresses pulmonary colonization by B16-F10 murine melanoma cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

774.95

C₄₁H₅₈N₈O₇

334994-34-2

{Nle}-Y-{Leu-(CH2-NH2)}-HPF

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. B J Yamamoto, et al. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor. J Pharmacol Exp Ther. 2010 Apr;333(1):161-73.  [Content Brief]